Austria Works On Method To Improve Price Transparency
Understanding Public R&D Funding May Lead To Better Pricing Policies
Austria’s health technology appraisal institute aims to further discussion on public investments in R&D and medicines pricing transparency.
You may also be interested in...
Many see the World Health Assembly resolution on drug pricing transparency as a game changer and welcome the fact that it will shine light on an area that critics says is far too opaque. Some are unhappy that the final version is not as strong as the original draft, but industry will be relieved the WHA ultimately did not adopt a requirement for mandatory disclosure of R&D costs.
The advanced therapies sector is undergoing something of an industrial revolution, but access issues for products coming to market remain, says Miguel Forte, CEO of Bone Therapeutics. However, there are opportunities to create a better environment for the sector, including regulatory change and more harmonization of HTA processes.
Member states of the Pan American Health Organization have approved a resolution to combine purchasing power to buy monkeypox vaccines.